Search Results
Oct 30, 2025, 11:00 ET Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting
presented at SITC. The Late-breaking Abstracts this year will only focus on late-breaking data from interventional clinical trials in humans and will further enhance the cutting-edge science offered at the 40th Anniversary Annual Meeting," said SITC Vice President Sandra Demaria MD. "SITC is committed
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
after EGFR-TKI progression, have been selected as a Late-Breaking Abstract at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (2025 SITC). Title: Final Overall Survival Analysis of HARMONi-A Study Comparing Ivonescimab Plus Chemotherapy to Chemotherapy
More news about: Akeso, Inc.
Oct 30, 2025, 08:00 ET Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting
will present new preclinical data on its lead product candidate, PLT012, in a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 5-9, 2025 in National Harbor, Maryland. "Immunometabolism is a key lever for overcoming
More news about: Pilatus Biosciences
Oct 28, 2025, 06:30 ET Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research
activation. This new automated multiomic workflow will be featured at the upcoming Society for Immunotherapy of Cancer (SITC) meeting taking place on November 7-8 in Washington, DC, at Booth 603. To learn more about the ProximityScope assay, please visit
More news about: Bio-Techne Corporation
Oct 27, 2025, 08:00 ET Pancreatic Cancer Clinical Trial Data for Diakonos Oncology's DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
immunotherapies to treat challenging and aggressive cancers, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, being held November 5-9 in National Harbor, MD.
More news about: Diakonos Oncology
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
HCB101 monotherapy and HCB101 in combination with standard of care in advanced cancers Society for Immunotherapy of Cancer (SITC), November 5-9, 2025– Two late-breaking poster presentations from HCB101-101 and HCB101-201, highlighting safety, pharmacology, and emerging
More news about: HanchorBio Inc.
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
progress to date. Phase 1/2 results of the STARt-001 clinical trial evaluating invikafusp alfa in antigen-rich solid tumors were first presented at SITC 2024, followed by disclosure of the recommended Phase 2 dose (RP2D) selection rationale and early clinical activity at AACR 2025.
More news about: Marengo Therapeutics
Oct 15, 2025, 07:00 ET Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4
preclinical data on its lead TriSTAR program, TriSTAR0701, a dual-payload T cell engager targeting Nectin-4, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland.
More news about: Marengo Therapeutics
Oct 06, 2025, 07:00 ET Compugen to Present at SITC 2025
in participants with advanced solid malignancies will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland. Poster presentation details:
More news about: Compugen Ltd.
Oct 03, 2025, 10:00 ET HanchorBio Announces Acceptance of HCB301 Abstract for Poster Presentation at SITC 2025 Annual Meeting
Significance of SITC Poster Presentations Acceptance for a poster presentation at the SITC Annual Meeting underscores the scientific rigor and innovation behind HCB301's development. SITC is the world's largest annual conference solely
More news about: HanchorBio Inc.
Sep 25, 2025, 10:15 ET ELEPHAS BIOSCIENCES WELCOMES DR. JEROME GALON TO THE COMPANY'S EXPANDING SCIENTIFIC ADVISORY BOARD
INSERM; director and co-founder of the European Academy of Tumor Immunology (EATI); and former board director of the Society of Immunotherapy of Cancer (SITC). On the commercial side, Galon co-founded and served as Chief Scientific Officer (CSO) of HalioDx, an immuno-oncology diagnostic company acquired by
More news about: Elephas
Sep 24, 2025, 07:00 ET Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director
the BMS International Immuno-Oncology Network (IION). Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer (SITC). Earlier in his career, Dr. Wigginton worked at the National Cancer Institute for 15 years and served as Head of the Investigational Biologics Section
More news about: Pathios Therapeutics